Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05040984

Enrollment

500

Registered

2021-09-10

Start date

2021-04-30

Completion date

2024-12-31

Last updated

2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overactive Bladder Syndrome

Brief summary

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Interventions

DRUGSolifenacin Oral Tablet

Solifenacin 1 tablet per day

DRUGMirabegron 25mg

Mirabegron 1 tablet per day

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* Women with overactive bladder syndrome received solifenacin or mirabegron as the initial treatment

Exclusion criteria

* \<20 year-old

Design outcomes

Primary

Measure	Time frame
Predictors of persistence of mirabegron versus solifenacin use	13 years

Countries

Taiwan

Contacts

Primary ContactSheng-Mou Hsiao, MD

smhsiao2@gmail.com+886919302632

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026